Free Trial
NASDAQ:HOWL

Werewolf Therapeutics Q4 2024 Earnings Report

Werewolf Therapeutics logo
$0.89 -0.01 (-0.71%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$0.92 +0.03 (+3.51%)
As of 04/25/2025 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Werewolf Therapeutics EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Werewolf Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Werewolf Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 11, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Werewolf Therapeutics' Q1 2025 earnings is scheduled for Friday, May 2, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Werewolf Therapeutics Earnings Headlines

Werewolf Therapeutics appoints Bloom as Chief Business Officer
Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
See More Werewolf Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Werewolf Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Werewolf Therapeutics and other key companies, straight to your email.

About Werewolf Therapeutics

Werewolf Therapeutics (NASDAQ:HOWL), a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

View Werewolf Therapeutics Profile

More Earnings Resources from MarketBeat